Is United Therapeutics (UTHR) Undervalued On Earnings And Its $2b Buyback?

Simply Wall St.11-07

United Therapeutics (UTHR) just paired third quarter 2026 earnings with a completed US$2.0b share repurchase, giving you fresh data on profitability, cash deployment, and how management is handling ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681810017?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-11-07 23:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681810017","market":"hk","top_or_hot":-1,"title":"Is United Therapeutics (UTHR) Undervalued On Earnings And Its $2b Buyback?","media":"Simply Wall St.","content":"<div>\n<p>United Therapeutics (UTHR) just paired third quarter 2026 earnings with a completed US$2.0b share repurchase, giving you fresh data on profitability, cash deployment, and how management is handling ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/is-united-therapeutics-uthr-undervalued-on-earnings-and-its\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is United Therapeutics (UTHR) Undervalued On Earnings And Its $2b Buyback?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs United Therapeutics (UTHR) Undervalued On Earnings And Its $2b Buyback?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-07 23:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/is-united-therapeutics-uthr-undervalued-on-earnings-and-its><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>United Therapeutics (UTHR) just paired third quarter 2026 earnings with a completed US$2.0b share repurchase, giving you fresh data on profitability, cash deployment, and how management is handling ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/is-united-therapeutics-uthr-undervalued-on-earnings-and-its\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/is-united-therapeutics-uthr-undervalued-on-earnings-and-its","article_id":"2681810017","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/is-united-therapeutics-uthr-undervalued-on-earnings-and-its","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681810017","pubTimestamp":1794065500,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 7, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗"},"translate_title":"United Therapeutics (UTHR) 的盈利及其 20 亿美元回购是否被低估？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1.5},"content_text":"United Therapeutics (UTHR) just paired third quarter 2026 earnings with a completed US$2.0b share repurchase, giving you fresh data on profitability, cash deployment, and how management is handling current product and pipeline spending. United Therapeutics shares trade at US$562.02, with the price easing 6.1% over the past week but still up 3.1% over 30 days and 13.2% year to date. Total shareholder return of 25.2% over one year and more than doubling over three and five years points to momentum that has built over time as investors weigh the latest earnings dip, the completed US$2.0b buyback, and fresh clinical trial progress. Compare United Therapeutics' buyback and pipeline mix with other healthcare groups reallocating cash into growth by scanning our hand picked 35 healthcare AI stocks. So after a softer quarter, a tight share count, and a stock that has already rewarded holders, does United Therapeutics still offer sufficient upside potential to justify the risks at this price, or has the balance shifted? AdvertisementMost Popular Narrative: 16% Undervalued On the most followed view, United Therapeutics carries a narrative fair value of about $671 per share versus a last close of $562.02. This frames the current pullback against a story built around pulmonary fibrosis, COPD related indications, and organ manufacturing.  Progress in organ replacement technologies, including three FDA authorized xenograft trials, designated pathogen free organ production facilities targeting several thousand organs per year and the approved LungFX device, lays out a path for new product lines that could add incremental revenue streams and operating leverage beyond the existing pulmonary business.  See why 34 investors see United Therapeutics as 16% undervalued. Result: Fair Value of $670.93 (UNDERVALUED) Still, the bullish United Therapeutics story can unravel quickly if Tyvaso uptake in pulmonary fibrosis underwhelms, or if competition erodes the shrinking base PAH franchise faster than expected. Find out about the key risks to this United Therapeutics narrative. Another View: What Multiples Say About United Therapeutics That 16% narrative discount looks appealing, but the current P/E of 19.4x already sits above the US Biotechs industry at 16.9x, even though it is well below peers at 52.2x and the fair ratio of 28x. Is the stock already pricing in a lot of good news, or is the gap to the fair ratio still worth betting on? For a closer look at how this pricing stacks up, including where the fair ratio might pull the market over time, See what the numbers say about this price — find out in our valuation breakdown.. NasdaqGS:UTHR P/E Ratio as at Nov 2026Next Steps Sentiment in this piece may lean cautiously optimistic, so move fast on your own homework and pressure test every assumption against the raw data. To see what has investors most encouraged about United Therapeutics right now, review the 2 key rewards. Looking for more investment ideas beyond United Therapeutics? If United Therapeutics has your attention, use that momentum and widen your watchlist with a few focused idea lists that target very different edges in the market.  Target potential mispricings by scanning companies that combine quality fundamentals with room for rerating through the 39 high quality undervalued stocks. Explore potential income streams by reviewing businesses with stronger yields and resilience using the 8 dividend fortresses. Dial down portfolio stress by hunting for sturdier balance sheets and consistent fundamentals inside the list of solid balance sheet and fundamentals (24 results).  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681810017","isCrawlerRequest":true}